SUBSCRIBE TO OUR RSS
Companies lined up in the IPO Queue.
The Burrill Report
July 20, 2011
[Please login to post comments]
23andMe Suspends Health-Related Gene Tests
Company responds to FDA demand and says will submit offering to regulatory review.
FDA Approves Breakthrough Therapy for Hepatitis C
Gilead’s oral pill will make treating the chronic condition easier.
Cancer Research Centers Partner to Launch Juno with $120M Series A
Startup will focus on immunotherapies.
Three Biotechs Secure Billion Dollar Partnerships
OncoMed, Molecular Partners, and Genmab could earn up to $6.3 billion if all the milestones are achieved.
Pharma Faces Shrinking Returns
Podcast: December 9, 2013
Lilly Discontinues Development of Experimental Drug for Major Depressive Disorder
The weekly round-up of failed trials, missed targets, and other business mishaps.
FDA Warns 23andMe to Stop Selling its DNA Tests
Agency says the DTC genetic testing firm needs its approval to market its kit and service.
Editas Medicine Launches with $43M in Funding
Biotech will use genome editing to develop new class of therapeutics.
Egalet Teams with Shionogi in $425M Deal
Partners will develop abuse-resistant pain pills.
Why Pharma Companies Are Looking More Like Biotechs
Podcast: December 2, 2013
Tweets from @burrillreport/biobuzz
Copyright 2013 Burrill & Company.
FACEBOOK AND TWITTER